Deficiency of purinergic P2X4 receptor alleviates experimental autoimmune hepatitis in mice
Biochemical Pharmacology · 2024
DOI: 10.1016/j.bcp.2024.116033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Zejin Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Infection and Immunity Institute and Translational Medical Center of Huaihe Hospital, Henan University, Kaifeng 475000, China. Hauptthemen laut MEDLINE: Hepatitis, Autoimmune, Receptors, Purinergic P2X4. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 93 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Development Fund, Henan University.
Abstract (Originalsprache)
Purinergic P2X4 receptor (P2X4R) has been shown to have immunomodulatory properties in infection, inflammation, and organ damage including liver regeneration and fibrosis. However, the mechanisms and pathophysiology associated with P2X4R during acute liver injury remain unknown. We used P2X4R-/- mice to explore the role of P2X4R in three different models of acute liver injury caused by concanavalin A (ConA), carbon tetrachloride, and acetaminophen. ConA treatment results in an increased expression of P2X4R in the liver of mice, which was positively correlated with higher levels of aspartate aminotransferase and alanine aminotransferase in the serum. However, P2X4R gene ablation significantly reduced the severity of acute hepatitis in mice caused by ConA, but not by carbon tetrachloride or acetaminophen. The protective benefits against immune-mediated acute hepatitis were achieved via modulating inflammation (Interleukin (IL)-1β, IL-6, IL-17A, interferon-γ, tumor necrosis factor-α), oxidative stress (malondialdehyde, superoxide dismutase, glutathione peroxidase, and catalase), apoptosis markers (Bax, Bcl-2, and Caspase-3), autophagy biomarkers (LC3, Beclin-1, and p62), and nucleotide oligomerization domain-likereceptorprotein 3(NLRP3) inflammasome-activated pyroptosis markers (NLRP3, Gasdermin D, Caspase-1, ASC, IL-1β). Additionally, administration of P2X4R antagonist (5-BDBD) or agonist (cytidine 5'-triphosphate) either improved or worsened ConA-induced autoimmune hepatitis, respectively. This study is the first to reveal that the absence of the P2X4 receptor may mitigate immune-mediated liver damage, potentially by restraining inflammation, oxidation, and programmed cell death mechanisms. And highlight P2X4 receptor is essential for ConA-induced acute hepatitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infection and Immunity Institute and Translational Medical Center of Huaihe Hospital, Henan University, Kaifeng 475000, China.
- Infection and Immunity Institute and Translational Medical Center of Huaihe Hospital, Henan University, Kaifeng 475000, China. Electronic address: jpwangchina@henu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Science and Technology Development Fund
- Henan University
Zitieren
APA
Liu, Z., Sun, M., Liu, W., Feng, F., Li, X., Jin, C., Zhang, Y., & Wang, J. (2024). Deficiency of purinergic P2X4 receptor alleviates experimental autoimmune hepatitis in mice. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116033
Vancouver
Liu Z, Sun M, Liu W, Feng F, Li X, Jin C, et al. Deficiency of purinergic P2X4 receptor alleviates experimental autoimmune hepatitis in mice. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116033
BibTeX
@article{Liu2024,
author = {Liu, Zejin and Sun, Mengyang and Liu, Wenhua and Feng, Fangyu and Li, Xinyu and Jin, Chaolei and Zhang, Yijie and Wang, Junpeng},
title = {Deficiency of purinergic P2X4 receptor alleviates experimental autoimmune hepatitis in mice},
journal = {Biochemical Pharmacology},
year = {2024},
doi = {10.1016/j.bcp.2024.116033}
}
EUVIMED